<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-98047</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Raltegravir in HIV-infected patients with high vascular risk</dc:title>
<dc:description xml:lang="en">Objectives: To record the experience with use of raltegravir (RTG) for devising highly active antiretroviral therapy (HAART) regimens based on RTG in high vascular risk patients. Methods:A retrospective study was conducted on high vascular risk patients taking RTG. Case was a patient who, at the time raltegravir was started, had &amp;#8805; 20% 10-year risk of cardiovascular disease, estimated by the algorithm of the European AIDS Clinical Society. Patients should have been on stable HAART including RTG for at least six months. A matched control with &amp;#8805; 20% risk of cardiovascular disease, was selected for each case. Results:Ten controls and ten cases were selected. After six months using RTG, a significant decreased was seen in levels of HDL cholesterol (median -2,5mg/dL in controls versus 2,5mg/dL in cases, p=0.015), triglycerides (10mg/dL versus -101mg/dL, p=0.009), and TC/HDL-C ratio (0.17 versus -0.73, p=0.002). Ten-year risk of cardiovascular disease was -4.85% in cases versus -0.05% in controls (p=0.07). Conclusions: RTG shows a good profile to be used in people with high vascular risk, with a decrease in TC/HDL-C ratio and vascular risk (AU)</dc:description>
<dc:creator>Torre, Javier de la</dc:creator>
<dc:creator>García-Alegría, Javier</dc:creator>
<dc:creator>Olalla, Julián</dc:creator>
<dc:creator>Salas, Daniel</dc:creator>
<dc:creator>del Arco, Alfonso</dc:creator>
<dc:creator>Prada, José Luis</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: Nos proponemos recoger la experiencia de uso de raltegravir en el contexto del tratamiento antirretroviral de gran actividad (TARGA) en pacientes de alto riesgo vascular. Método: Estudio retrospectivo de casos y controles. Los casos fueron aquellos pacientes que al comenzar con raltegravir presentaban un riesgo de enfermedad cardiovascular &amp;#8805; 20% según el algoritmo de la Sociedad Europea de Sida. Debían haber permanecido con dicho tratamiento durante al menos seis meses. Se parearon controles 1:1 con riesgo vascular también &amp;#8805; 20%.Resultados: Se seleccionaron diez casos y diez controles. Tras seis meses de uso de raltegravir, se observó un descenso de los valores de colesterol unido a lipoproteínas de alta densidad (colesterol HDL) (-2,5mg/dL en los controles frente a 2,5mg/dL en los casos, p=0,015), triglicéridos (10mg/dL frente a -101mg/dL, p=0,009), y en la ratio colesterol total/colesterol HDL (0,17 frente a -0,73, p=0,002). El riesgo de enfermedad cardiovascular a diez años disminuyó un 4,85% en los casos frente a un 0,05% en los controles (p=0,07). Conclusiones: Raltegravir muestra un buen perfil para ser usado en pacientes de alto riesgo vascular, con descenso de la ratio colesterol total/colesterol HDL y del riesgo vascular (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);138(3): 107-109, feb. 2012.</dc:source>
<dc:identifier>ibc-98047</dc:identifier>
<dc:title xml:lang="es">Raltegravir en pacientes con infección por el virus de la inmunodeficiencia humana y alto riesgo vascular</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d33014^s22073</dc:subject>
<dc:subject>^d33075^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7117^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201202</dc:date>
</metadata>
</record>
</ibecs-document>
